We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Nanomaterial-based Biosensors for Near-patient Testing

Nanomaterial-based Biosensors for Near-patient Testing content piece image
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

BioMed X has announced the completion of their first research collaboration project with Roche Diagnostics in the field of nanomaterial-based biosensors for near-patient testing. BioMed X successfully achieved the proof of principle for a new sensor platform allowing the analysis of several different parameters from blood samples with one single device.

The project was initiated in 2015 as a call for application using BioMed X’s proprietary crowdsourcing platform for project proposals. As a result of an international innovation challenge, a team of early-career researchers from five different countries worked in Heidelberg on the design of a field effect transistor-based multimodal sensing platform for proteins, blood gases and electrolytes, metabolites and enzymes with a single-use disposable material for point-of-care diagnostics.

The team successfully demonstrated the first highly sensitive label-free detection of thyroid-stimulating hormone (TSH) in undiluted human serum on a new FET sensor design based on gold and graphene. A fundamental limit to previous sensor designs, known as Debye screening, was overcome by specific modification of the sensor surfaces. Meanwhile, the sensor design has been further refined and the goal was met to show proof-of-principle for the multimodal sensing platform allowing detection of multiple analytes from whole human blood samples.